🔥 CYBER MONDAY SALE ENDS TONIGHT: Save 30% or more on all Examine products Save now »

Studies related to Hematocrit and Cannabis

Cannabis Induces A Clinical Response In Patients With Crohn's Disease: A Prospective Placebo-controlled Study

Effect None
Values g/dl. Mean and standard deviation. Placebo: before 38 ± 5, after 37 ± 6. Intervention: before 39.4 ± 3, after 35.1 ± 4.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 21
Sex Both Genders
Notes for this study:
In a randomized, placebo-controlled trial, 21 participants with Crohn's disease smoked cannabis cigarettes containing 115 mg of THC or placebo with THC removed for 8 weeks.

The primary outcome was remission of Crohn's disease, defined as a Crohn's Disease Activity Index score of 150 or less, and 5 participants in the cannabis group and 1 in the placebo group achieved remission, though this wasn't statistically significant. The overall score was notably lower after 2 and 8 weeks. l count, or c-reactive protein, There wasn't a statistically significant change in hemoglobin, hematocrit, white blood cell count.